Abstract

Genetic predisposition plays a pivotal role in the development of ovarian cancer, with mutations in genes such as BRCA1 and BRCA2 significantly increasing the risk. This article explores the implications of genetic predisposition and risk assessment for ovarian cancer, focusing on their impact on screening and prevention strategies. Key genetic markers, screening modalities, risk-reducing interventions, and challenges in clinical implementation are discussed. Advances in genomic research have transformed our understanding of ovarian cancer susceptibility, paving the way for personalized approaches to early detection and prevention.